More about

Infliximab

News
June 05, 2022
2 min read
Save

Infliximab may lead to higher infection rate, no improvement in transplant outcomes

Infliximab may lead to higher infection rate, no improvement in transplant outcomes

The use of infliximab in patients with a deceased donor kidney transplant led to increased infections and did not improve allograft survival, according to data presented at the American Transplant Congress.

News
May 24, 2022
1 min read
Save

Researchers observe no difference between subcutaneous and IV infliximab treatment in IBD

Researchers observe no difference between subcutaneous and IV infliximab treatment in IBD

SAN DIEGO — Subcutaneous infliximab maintained remission among patients with inflammatory bowel disease who switched from IV dosing, according to research presented at Digestive Disease Week.

News
April 20, 2022
15 min watch
Save

VIDEO: Hidradenitis suppurativa patient experience, management, care ‘key themes’ at meeting

VIDEO: Hidradenitis suppurativa patient experience, management, care ‘key themes’ at meeting

In this video, Haley Naik, MD, discusses “three key themes” from the hidradenitis suppurativa symposiums at the American Academy of Dermatology Annual Meeting.

News
April 12, 2022
1 min watch
Save

VIDEO: Advanced hidradenitis suppurativa management requires varied, creative strategies

VIDEO: Advanced hidradenitis suppurativa management requires varied, creative strategies

In this video, Christopher Sayed, MD, discusses “pearls” from the advanced management of hidradenitis suppurativa symposium at the American Academy of Dermatology Annual Meeting.

News
February 17, 2022
2 min read
Save

After sustained CD remission, risk of relapse higher with infliximab withdrawal

Patients with Crohn’s disease who stopped infliximab had a significantly higher risk of relapse vs. those who continued combination therapy, according to results presented at the Congress of the European Crohn’s and Colitis Organization.

News
January 31, 2022
3 min read
Save

Norway 'excellent example' of how to increase access to biosimilars

Norway 'excellent example' of how to increase access to biosimilars

The European Union, and specifically Norway, has demonstrated successful strategies for making biosimilars available for patients — and realizing “tremendous savings” — that should be adopted in the United States, according to an analysis.

News
January 20, 2022
2 min read
Save

Biosimilar, originator DMARDs exhibit no differences in treatment retention

Biosimilar, originator DMARDs exhibit no differences in treatment retention

There are no clinically relevant differences in treatment retention among patients receiving biosimilar or originator biologic disease-modifying antirheumatic drugs as first exposure to that drug, data published in Rheumatology show.

News
January 11, 2022
2 min read
Save

Early anti-TNF induction may link to long-term fistula healing in Crohns disease

Early anti-TNF induction may link to long-term fistula healing in Crohns disease

Early infliximab therapy initiation following surgery may result in long-term fistula healing among patients with perianal fistulizing Crohn’s disease, according to research published in BMC Gastroenterology.

News
January 06, 2022
1 min read
Save

Therapeutic drug monitoring sustains disease control during infliximab maintenance

Therapeutic drug monitoring sustains disease control during infliximab maintenance

Proactive therapeutic drug monitoring sustained disease control without disease worsening among patients with immune-mediated inflammatory diseases undergoing infliximab maintenance therapy, according to study results.

News
January 04, 2022
2 min read
Save

Biologic therapy, small molecules induce remission in ulcerative colitis

Biologic therapy, small molecules induce remission in ulcerative colitis

Compared with placebo, most biologic and small molecule therapies correlated with superiority for the induction of remission in moderate to severe ulcerative colitis, according to research published in Gut.

View more